The Fertility Providers Alliance, a leading advocate for family-building access and equitable fertility care, today strongly commends President Trump for his guidance on employer-provided coverage for fertility care and “most favored nation” pricing for fertility medications. This action signals real momentum toward making family building more attainable for millions of Americans.

“Infertility affects one in six women of reproductive age, yet only one in four large employers currently offer I.V.F. coverage,” said FPA President TJ Farnsworth. “By treating infertility benefits as a standalone offering, this policy opens the door for more businesses—especially small employers—to support their workforce in building families.”

“Similarly, fertility drug costs can represent over 20% of the total cost of care for patients in I.V.F treatment, and the President’s most favored nation pricing for these medications will have a dramatic impact on reducing costs to patients."

We believe the President’s policy will help remove a major barrier: the cost and fragmentation of fertility care. For too long, couples and individuals facing infertility have faced not only the emotional burden of treatment but also the financial burden—often paying tens of thousands of dollars per IVF cycle out of pocket.

Why this matters:

• Fertility medications are a critical component of treatment, and pricing reform is essential to making care truly accessible.
• IVF is often excluded (or only partially covered) in employer health plans, despite being a medically recognized treatment for the disease of infertility.
• While employees value IVF benefits, only a fraction of employers offer IVF coverage today.

 What this policy can unlock:  

• A pathway for employers—large and small—to expand benefits options by offering separate IVF insurance products, giving employees more control and better access to fertility care.
• A stronger signal to Congress, state regulators, and the private sector that infertility is a serious medical condition deserving of insurance protection—not an elective or optional “perk.”
• Improved outcomes in family formation, population health, and reproductive equity, especially for under-resourced communities and historically underinsured populations.

While today’s guidance is a landmark step forward, real change will depend on implementation and buy-in from payers and employers. We call on:

1. Employers to act boldly by offering stand-alone IVF insurance options (or expanding fertility benefits broadly) as a standard benefit, not a luxury.
2. Insurers to design products that cover full-cycle IVF, including associated procedures (e.g. embryo freezing, medications, genetics, and storage) under transparent terms.
3. Policymakers and regulators to support and incentivize fertility coverage expansion—whether via tax credits, mandates, or public-private partnerships.
4. Advocacy groups and patient communities to remain vigilant, engaged, and vocal to ensure the promise of this order becomes reality, not just rhetoric.

The Fertility Providers Alliance remains committed to advocating for policies that promote access, affordability, and awareness of infertility treatment nationwide. We look forward to working with the Administration and Congress to achieve this goal.